ReviewMolecules (Basel, Switzerland)2015
Small-Molecule Inhibitors of the Type III Secretion System.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Houttuynia cordata extract protects against Salmonella infection by targeting type III secretion system 1.Poultry science · 2026Article
- Targeting Type III Secretion System usingIndian journal of microbiology · 2025Review
- A comprehensive review of the pathogenic mechanisms ofFrontiers in microbiology · 2025Review
- Contribution of the infection ecosystem and biogeography to antibiotic failure in vivo.npj antimicrobials and resistance · 2024Review
- Research Progress on Small Molecular Inhibitors of the Type 3 Secretion System.Molecules (Basel, Switzerland) · 2022Review
- A Brominated Furanone InhibitsBiomedicines · 2022Article
- Article
- TheMicroorganisms · 2021Review
- Fluorescence Detection of Type III Secretion Using a Glu-CyFur Reporter System inMicroorganisms · 2020Article
- Innovation and Application of the Type III Secretion System Inhibitors in Plant Pathogenic Bacteria.Microorganisms · 2020Review
- Comprehensive Host Cell-Based Screening Assays for Identification of Anti-Virulence Drugs TargetingMicroorganisms · 2020Article
- Novel Noncompetitive Type Three Secretion System ATPase Inhibitors Shut DownBiochemistry · 2020Article
- A Review of the Functional Annotations of Important Genes in the AHPND-Causing pVA1 Plasmid.Microorganisms · 2020Review
- Chemical Targeting and Manipulation of Type III Secretion in the Phytopathogen Xanthomonas campestris for Control of Disease.Applied and environmental microbiology · 2020Article
- High-resolution view of the type III secretion export apparatus in situ reveals membrane remodeling and a secretion pathway.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle ofACS central science · 2019Article
- In Silico Screening and Analysis of Broad-Spectrum Molecular Targets and Lead Compounds for Diarrhea Therapy.Bioinformatics and biology insights · 2019Article
- Protein-Injection Machines in Bacteria.Cell · 2018Review
- High-Throughput Screening for Bacterial Glycosyltransferase Inhibitors.Frontiers in cellular and infection microbiology · 2018Article
- Small Molecule Inhibitor of Type Three Secretion System Belonging to a Class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones Improves Survival and Decreases Bacterial Loads in an AirwayBioMed research international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant pathogens have presented increasing challenges to the discovery and development of new antibacterial agents. The type III secretion system (T3SS), existing in bacterial chromosomes or plasmids, is one of the most complicated protein secretion systems. T3SSs of animal and plant pathogens possess many highly conserved main structural components comprised of about 20 proteins. Many Gram-negative bacteria carry T3SS as a major virulence determinant, and using the T3SS, the bacteria secrete and inject effector proteins into target host cells, triggering disease symptoms. Therefore, T3SS has emerged as an attractive target for antimicrobial therapeutics. In recent years, many T3SS-targeting small-molecule inhibitors have been discovered; these inhibitors prevent the bacteria from injecting effector proteins and from causing pathophysiology in host cells. Targeting the virulence of Gram-negative pathogens, rather than their survival, is an innovative and promising approach that may greatly reduce selection pressures on pathogens to develop drug-resistant mutations. This article summarizes recent progress in the search for promising small-molecule T3SS inhibitors that target the secretion and translocation of bacterial effector proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.